Stelara (Ustekinumab) Denied by Insurance: Appeal Guide

Stelara (ustekinumab) is a biologic medication manufactured by Janssen (Johnson & Johnson) that targets the IL-12 and IL-23 cytokine pathways. It is FDA-approved for moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. Stelara's unique mechanism — and its dosing schedule of every 8–12 weeks for maintenance — makes it a preferred option for many patients with inflammatory conditions. However, insurance denials are common, and navigating the appeal process requires understanding the specific barriers insurers put in place.

Why Insurance Denies Stelara

Step therapy requiring prior biologic failure is the most significant barrier. Insurers treating Stelara as a second- or third-line biologic routinely require documented failure of at least one TNF inhibitor (such as adalimumab, etanercept, or infliximab) before approving ustekinumab. For Crohn's disease and UC, the required step drugs may also include conventional immunomodulators like azathioprine or 6-mercaptopurine. This requirement exists even when there are clinical reasons to prefer Stelara as a first biologic — such as a higher risk of demyelinating disease or certain cancers that may be associated with TNF inhibitor use.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization is mandatory for Stelara across all indications. The PA process requires a confirmed diagnosis, active disease severity documentation, and a complete prior treatment history. Missing documentation is the most preventable reason for initial PA denials.

Biosimilar substitution issues are a growing problem as Wezlana (ustekinumab-auub, from Amgen) and other biosimilars enter the market. Some insurers are moving Stelara off formulary entirely, requiring patients — even those stable on brand Stelara for years — to switch to a biosimilar. While biosimilars are generally considered equivalent, switching a stable patient can raise legitimate clinical concerns, including immunogenicity (development of antibodies to the new formulation) that your physician can document.

Formulary non-placement is another denial reason. If Stelara is not on your plan's formulary at all, you will need a formulary exception, which requires demonstrating medical necessity for Stelara specifically over any covered alternatives.

How to Appeal a Stelara Denial

Document prior biologic or conventional therapy failure in detail. Your appeal must include dates, drug names, doses, duration of treatment, and specific reasons each prior therapy failed. For TNF inhibitor failure, provide clinical notes, lab values, and disease activity scores from the period when the drug was tried. If TNF inhibitors were contraindicated (such as for a patient with a demyelinating condition or active serious infection history), document this as an explicit contraindication rather than simply a preference.

Provide objective disease activity scores. For psoriasis, include PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area affected), or DLQI (Dermatology Life Quality Index) scores demonstrating moderate-to-severe disease. For Crohn's disease, provide CDAI or Harvey-Bradshaw Index scores. For UC, provide Mayo Clinic Score or Partial Mayo Score documentation.

Have your physician address biosimilar switching. If your insurer is requiring a switch from brand Stelara to a biosimilar and you are a stable, long-term Stelara patient, your gastroenterologist or dermatologist should write a letter explaining the clinical rationale for continuing brand Stelara. While this letter may not always succeed, it creates a record and can support an external appeal.

Cite clinical guidelines. ACG (American College of Gastroenterology) guidelines for Crohn's disease and UC support ustekinumab as a first-line biologic option for patients who prefer it or have contraindications to TNF inhibitors. AAD guidelines support biologic therapy for moderate-to-severe psoriasis. Reference these guidelines explicitly.

Request peer-to-peer review. Your prescribing physician should request a direct conversation with the insurer's medical reviewer. This is especially effective for step therapy overrides, where the clinical rationale for skipping an intermediate step is best explained by a specialist.

Appeal to the External Independent Review: Complete Guide" class="auto-link">external reviewer. Independent external review organizations overturn biologic denials at meaningful rates, particularly when the clinical documentation is strong and the denial is based on step therapy requirements that your physician has shown are clinically inappropriate.

Patient Assistance Programs

Janssen offers the Janssen Patient Assistance Program (JPAP) for uninsured or underinsured patients who cannot afford Stelara. The program provides free Stelara to qualifying patients. Visit janssenprescriptionassistance.com or call 1-800-652-6227. Janssen CarePath also offers copay assistance for commercially insured patients.

Stelara has a list price of approximately $20,000–$25,000 per dose for the IV induction dose (Crohn's/UC) or $16,000–$18,000 per subcutaneous injection, making patient assistance and copay support critical.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?